Monisha Medhi
Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1104016096
Payments from drug & device makers
Across 180 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$520
- Amgen$454
- Tandem Diabetes Care, Inc.$394
- Novo Nordisk$279
- AstraZeneca$237
- BD$226
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,95699%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $520 |
| Amgen(2 entities) | 15 | $454 |
| Tandem Diabetes Care, Inc. | 6 | $394 |
| Novo Nordisk | 14 | $279 |
| AstraZeneca(2 entities) | 12 | $237 |
| BD | 12 | $226 |
| Sanofi-aventis U.S. LLC | 11 | $207 |
| Boehringer Ingelheim | 13 | $204 |
| Amneal Pharmaceuticals LLC | 6 | $149 |
| Esperion Therapeutics, Inc. | 1 | $131 |
| AbbVie | 6 | $129 |
| Radius Health, Inc. | 6 | $106 |
| Abbott | 6 | $102 |
| Bayer | 5 | $94 |
| Insulet Corporation | 5 | $92 |
| Xeris Pharmaceuticals, Inc. | 5 | $89 |
| Medtronic(2 entities) | 6 | $88 |
| Amarin Pharma, Inc. | 2 | $78 |
| Dexcom, Inc. | 4 | $75 |
| Corcept Therapeutics | 3 | $53 |
| Pfizer | 3 | $44 |
| Embecta Corp. | 2 | $42 |
| Ascendis Pharma Endocrinology Inc | 1 | $31 |
| Shire North American Group Inc | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| BETA Bionics, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$243
- NEXLIZET$131
- NEXLETOL$131
- EVENITY$115
- TEPEZZA$114
How this compares
$3,983 in reported general payments places this provider in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 138 | $166,307 |
| OzempicSemaglutide | 89 | $139,327 |
| TrulicityDulaglutide | 79 | $133,250 |
| SomavertPegvisomant | 11 | $88,535 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $61,208 |
| Humalog Kwikpen U-100Insulin Lispro | 114 | $43,739 |
| FarxigaDapagliflozin Propanediol | 30 | $41,282 |
| Cinacalcet Hcl | 19 | $39,601 |
| SynthroidLevothyroxine Sodium | 406 | $38,759 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $36,300 |
| TradjentaLinagliptin | 41 | $33,491 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $32,409 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $28,475 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $23,246 |
| ProliaDenosumab | 14 | $21,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $204 | $211,670191 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $520 | $153,537107 claims |
| Novo NordiskOzempic, Novolog | $279 | $142,636100 claims |
| PfizerSomavert, Levoxyl | $44 | $89,79640 claims |
| AstraZenecaFarxiga | $237 | $41,28230 claims |
| AbbVieSynthroid | $129 | $38,759406 claims |
| AmgenProlia | $454 | $21,91914 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $149 | $13,823804 claims |
| MerckJanuvia | $11 | $11,89512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Pittsburgh
- Vijay BahlPittsburgh$998K
- Erin KershawPittsburgh$804K
- Murray GordonPittsburgh$576K
- Swarna VarmaPittsburgh$520K
- Sachin BahlPittsburgh$162K
- Peter GrondziowskiPittsburgh$143K
- Patricia BononiPittsburgh$107K
- Frederico ToledoPittsburgh$92K
- Esra Karslioglu FrenchPittsburgh$73K
- Mona Al MukaddamPhiladelphia$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.